Angiodysplasia secondary prevention

Angiodysplasia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Angiodysplasia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Angiodysplasia secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Angiodysplasia secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Angiodysplasia secondary prevention
CDC on Angiodysplasia secondary prevention
Angiodysplasia secondary prevention in the news
Blogs on Angiodysplasia secondary prevention
Directions to Hospitals Treating Angiodysplasia
Risk calculators and risk factors for Angiodysplasia secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nikita Singh, M.D.[2]

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Secondary Prevention

Secondary prevention aims to reduce the impacts of the disease after it has already occurred. The role of vasoactive drugs in the prevention of acute bleeding events in angiodysplasia is still ambiguous.